Neuronetics, Inc. revenue by segment STIM

Neuronetics, Inc. splits its revenue into 2 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Services at $26.2 million, 62% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Sep 30, 2026
Q3 FY2026
Sep 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Q1 FY2025
Mar 31, 2025
Q4 FY2024
Dec 31, 2024
Revenue
160
42
42
34
42
37
38
32
22
Services
98
share 61.4%
26
+20.1%
share 62.4%
27
+16.8%
share 64.7%
22
+15.4%
share 62.5%
23
share 56.2%
22
share 58.5%
23
share 60.4%
19
share 58.4%
—
Product
62
share 38.6%
16
+1.8%
share 37.6%
15
-2.7%
share 35.3%
13
-2.9%
share 37.5%
18
share 43.8%
15
share 41.5%
15
share 39.6%
13
share 41.6%
—
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
STIM (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Malvern, PA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1227636
Former names
Neuronetics, Inc. (until Nov 4, 2026); NEURONETICS INC (until Aug 16, 2006)

Other Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.